Quick Answer
ARS Pharmaceuticals, Inc. reported Total Revenue of $84.28 million for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -5.5% in Total Revenue from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $663.0 thousand | Q2 2022: $464.0 thousand | Q3 2022: $189.0 thousand | Q1 2023: $20.0 thousand | Q2 2023: $10.0 thousand | Q3 2023: $0.00 | Q1 2024: $0.00 | Q2 2024: $500.0 thousand | Q3 2024: $2.07 million | Q1 2025: $7.97 million | Q2 2025: $15.72 million | Q3 2025: $32.50 million.
- Over the full 5 years of available data (2021 to 2025), ARS Pharmaceuticals, Inc.'s Total Revenue has grown by 1,430.7%.
- Historical annual values: Fiscal year 2025: $84.28 million | Fiscal year 2024: $89.15 million | Fiscal year 2023: $30.0 thousand | Fiscal year 2022: $1.32 million | Fiscal year 2021: $5.51 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: